{"id":"mirv","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"00c424b5-6ccd-48ab-9e88-1986451120e2","title":"ELAHERE (MIRVETUXIMAB SORAVTANSINE) INJECTION, SOLUTION [IMMUNOGEN, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mIRV is a recombinant RSV vaccine candidate designed to induce both humoral and cellular immunity against multiple RSV antigens. By presenting multiple RSV epitopes, the vaccine aims to provide broad protection against RSV infection across different age groups and RSV strains.","oneSentence":"mIRV is a multivalent respiratory syncytial virus (RSV) vaccine that stimulates immune responses against RSV to prevent infection and disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:21:30.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of respiratory syncytial virus (RSV) infection in adults and older adults"}]},"trialDetails":[{"nctId":"NCT06365853","phase":"PHASE2","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-29","conditions":"Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive","enrollment":100},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT06890338","phase":"PHASE2","title":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-21","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":140},{"nctId":"NCT05445778","phase":"PHASE3","title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-03-15","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":520},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100},{"nctId":"NCT06682988","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-05-28","conditions":"Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers","enrollment":110},{"nctId":"NCT05041257","phase":"PHASE2","title":"Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-10-19","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":79},{"nctId":"NCT05483933","phase":"PHASE1","title":"Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers","status":"COMPLETED","sponsor":"Shattuck Labs, Inc.","startDate":"2022-08-18","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT07059845","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-13","conditions":"Ovarian Cancer","enrollment":320},{"nctId":"NCT05887609","phase":"PHASE2","title":"An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-10-03","conditions":"Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":53},{"nctId":"NCT05456685","phase":"PHASE2","title":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-09-28","conditions":"High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer","enrollment":125},{"nctId":"NCT04606914","phase":"PHASE2","title":"Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-05-27","conditions":"Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer","enrollment":70},{"nctId":"NCT04209855","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-12-31","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":453},{"nctId":"NCT04296890","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression","status":"COMPLETED","sponsor":"ImmunoGen, Inc.","startDate":"2020-07-23","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":106},{"nctId":"NCT05052697","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-13","conditions":"Influenza, Human","enrollment":1158},{"nctId":"NCT05622890","phase":"PHASE3","title":"A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer","status":"UNKNOWN","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2022-08-18","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":35},{"nctId":"NCT02631876","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"ImmunoGen, Inc.","startDate":"2016-03-02","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer","enrollment":366}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"mIRV","genericName":"mIRV","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"mIRV is a multivalent respiratory syncytial virus (RSV) vaccine that stimulates immune responses against RSV to prevent infection and disease. Used for Prevention of respiratory syncytial virus (RSV) infection in adults and older adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}